Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

Biblos-e Archivo/Manakin Repository

Files in this item

Thumbnail
Share

Delicious Save this on Delicious

Citations

This item appears in the following Collection(s)